Loading stock data…
$6.54-0.03 (-0.38%)
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.
Cartesian Therapeutics, Inc. in the Healthcare sector is trading at $6.54 with a market capitalization of $264M. Wall Street consensus targets $33.67 (6 analysts), implying a +414.4% move over the next 12 months. The stock is currently near its 52-week low of $5.60, remaining 15.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $78,000↓ | $947,000↑ | $452,000↑ | $298,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$29.16M↓ | -$26.50M↓ | -$21.94M↓ | -$21.07M↑ | -$21.81M |
| Net Income | $15.77M↑ | -$39.18M↑ | -$92.58M↓ | -$35.90M↓ | $15.89M |
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cel...